AEON Biopharma, Inc. (NASDAQ:AEON) Sees Large Growth in Short Interest

AEON Biopharma, Inc. (NASDAQ:AEON) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 226,400 shares, an increase of 98.2% from the September 30th total of 114,200 shares. Based on an average daily volume of 188,200 shares, the days-to-cover ratio is currently 1.2 days. Approximately 2.4% of the company’s shares are short sold. Approximately 2.4% of the company’s shares are short sold. Based on an average daily volume of 188,200 shares, the days-to-cover ratio is currently 1.2 days.

Analysts Set New Price Targets

Separately, Aegis reaffirmed a “buy” rating on shares of AEON Biopharma in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy”.

AEON Biopharma Stock Up 0.7%

Shares of NASDAQ AEON opened at $0.85 on Friday. The company has a market capitalization of $9.90 million, a PE ratio of 4.72 and a beta of 0.74. AEON Biopharma has a twelve month low of $0.38 and a twelve month high of $66.74. The firm has a fifty day simple moving average of $0.87 and a 200 day simple moving average of $0.74.

Institutional Investors Weigh In On AEON Biopharma

A hedge fund recently bought a new stake in AEON Biopharma stock. Dauntless Investment Group LLC bought a new position in AEON Biopharma, Inc. (NASDAQ:AEON) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,025,000 shares of the company’s stock, valued at approximately $594,000. AEON Biopharma makes up approximately 0.7% of Dauntless Investment Group LLC’s investment portfolio, making the stock its 18th biggest position. Dauntless Investment Group LLC owned about 9.73% of AEON Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.